系统性轻链型淀粉样变性并发致命性自发性脾破裂1例报告

李朵; 赵英仁; 陈红梅

doi:10.3969/j.issn.1001-5256.2022.08.032

系统性轻链型淀粉样变性并发致命性自发性脾破裂1例报告

DOI: 10.3969/j.issn.1001-5256.2022.08.032

西安交通大学第一附属医院感染科，西安 710061

基金项目:

陕西省自然科学基础研究计划项目 (2018JM7146)

伦理学声明：本例报道已获得患者家属知情同意。

利益冲突声明：所有作者均声明不存在利益冲突。

作者贡献声明：李朵负责采集数据，分析数据，查阅文献，撰写论文；赵英仁、陈红梅负责设计课题，审阅文章内容并最终定稿。

详细信息

通信作者:
陈红梅，chenhongmei1107@126.com

计量
- 文章访问数: 241
- HTML全文浏览量: 114
- PDF下载量: 32
- 被引次数: 0
出版历程
- 收稿日期: 2021-09-29
- 录用日期: 2021-11-17
- 出版日期: 2022-08-20

A case of systemic light-chain amyloidosis with fatal spontaneous splenic rupture

Department of Infectious Diseases, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, China

Research funding:

Shaanxi Provincial Natural Science Basic Research Project (2018JM7146)

More Information

Corresponding author: CHEN Hongmei, chenhongmei1107@126.com(ORCID:0000-0003-1002-9790)

摘要

- 淀粉样变性 /
- 脾破裂 /
- 肝疾病
- A myloidosis /
- Splenic Rupture /
- Liver Diseases

HTML全文

图 1 肝脾CT影像学表现

注：a, 腹部平扫CT; b，肝血管成像; c, 腹部增强CT; d, 腹部大血管造影。

Figure 1. CT imaging findings of liver and spleen

下载: 全尺寸图片幻灯片

图 2 肝组织刚果红染色(×100)

注：箭头示局部肝窦内皮血管化，胆小管显著增生。

Figure 2. Congo red staining of liver tissue(×100)

下载: 全尺寸图片幻灯片

图 3 脾组织刚果红染色(×100)

注：箭头示血管壁可见红染无结构物沉积。

Figure 3. Congo red staining of spleen tissue(×100)

下载: 全尺寸图片幻灯片

参考文献(13)

[1]	LU J. Progress of diagnosis and treatment of systemic light chain amyloidosis[J]. J Clin Hematol, 2021, 34(3): 205-209. DOI: 10.13201/j.issn.1004-2806.2021.03.013. 路瑾. 系统性轻链型淀粉样变性的诊治进展[J]. 临床血液学杂志, 2021, 34(3): 205-209. DOI: 10.13201/j.issn.1004-2806.2021.03.013.
[2]	HUANG XH, LIU ZH. The Clinical presentation and management of systemic light-chain amyloidosis in China[J]. Kidney Dis (Basel), 2016, 2(1): 1-9. DOI: 10.1159/000444287.
[3]	GERTZ MA, COMENZO R, FALK RH, et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004[J]. Am J Hematol, 2005, 79(4): 319-328. DOI: 10.1002/ajh.20381.
[4]	RAJKUMAR SV, GERTZ MA, KYLE RA. Prognosis of patients with primary systemic amyloidosis who present with dominant neuropathy[J]. Am J Med, 1998, 104(3): 232-237. DOI: 10.1016/s0002-9343(98)00037-0.
[5]	CELLI BR, RUBINOW A, COHEN AS, et al. Patterns of pulmonary involvement in systemic amyloidosis[J]. Chest, 1978, 74(5): 543-547. DOI: 10.1378/chest.74.5.543.
[6]	SHIENTAG LJ, CABRERA OA, PAZOUR GJ. Allelic diversity in the serum amyloid A2 gene and amyloid a amyloidosis in a breeding colony of zebra finches (taeniopygia guttata)[J]. Comp Med, 2019, 69(5): 425-431. DOI: 10.30802/AALAS-CM-18-000139.
[7]	MEI JG, SHAO LJ, CAO HQ, et al. Detection and analysis of cytogenetic abnormalities in systemic AL amyloidosis[J]. Lab Med Clin, 2016, 13(24): 3463-3466. DOI: 10.3969/j.issn.1672-9455.2016.24.011. 梅建刚, 邵靓婧, 曹红琴, 等. 系统性轻链型淀粉样变性细胞遗传学异常检测分析[J]. 检验医学与临床, 2016, 13(24): 3463-3466. DOI: 10.3969/j.issn.1672-9455.2016.24.011.
[8]	GUNATHILAKA ML, NIRIELLA MA, LUKE NV, et al. Possible gasoline- induced chronic liver injury due to occupational malpractice in a motor mechanic: a case report[J]. J Med Case Rep, 2017, 11(1): 179. DOI: 10.1186/s13256-017-1352-x.
[9]	GERTZ MA. Immunoglobulin light chain amyloidosis: 2020 update on diagnosis, prognosis, and treatment[J]. Am J Hematol, 2020, 95(7): 848-860. DOI: 10.1002/ajh.25819.
[10]	COLOMBAT M, ALDIGIER JC, ROTHSCHILD PR, et al. New clinical forms of hereditary apoA-I amyloidosis entail both glomerular and retinal amyloidosis[J]. Kidney Int, 2020, 98(1): 195-208. DOI: 10.1016/j.kint.2020.03.033.
[11]	SHEN ZY. Development and innovation of liver transplantation in China[J]. J Clin Hepatol, 2019, 35(11): 2377-2385. DOI: 10.3969/j.issn.1001-5256.2019.11.001. 沈中阳. 中国肝移植的发展与创新[J]. 临床肝胆病杂志, 2019, 35(11): 2377-2385. DOI: 10.3969/j.issn.1001-5256.2019.11.001.
[12]	PALLADINI G, DISPENZIERI A, GERTZ MA, et al. New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes[J]. J Clin Oncol, 2012, 30(36): 4541-4549. DOI: 10.1200/JCO.2011.37.7614.
[13]	GODARA A, TOSKIC D, ALBANESE J, et al. Involved free light chains < 10 mg/L with treatment predict better outcomes in systemic light-chain amyloidosis[J]. Am J Hematol, 2021, 96(1): E20-E23. DOI: 10.1002/ajh.26025.